Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma

Pappa, C.; Tsirakis, G.; Psarakis, F.; Kolovou, A.; Tsigaridaki, M.; Stafylaki, D.; Sfiridaki, K.; Alexandrakis, M.
March 2013
Medical Oncology;Mar2013, Vol. 30 Issue 1, p1
Academic Journal
There are many growth factors influencing the expansion of multiple myeloma (MM). Angiogenesis is a process that may enhance MM growth, in various manners. Among them, insulin-like growth factor-1 (IGF-1) is a major factor, acting in many levels. The aim of the study was to measure serum levels of IGF-1 in newly diagnosed MM patients and to correlate them with clinical stage of the disease and with markers of angiogenesis, such as vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and interleukin-6 and 15 (IL-6 and IL-15). Serum levels of the above factors were measured, by ELISA, in 57 newly diagnosed MM patients and in 20 healthy controls. There was no difference in serum levels of IGF-1 in MM patients and in controls, contrary to angiogenic factors, which were higher in MM patients ( p < 0.001). Similarly, IGF-1 did not correlate with clinical stage of the disease nor the other angiogenic factors, which also correlated with each other ( p < 0.001). Serum IGF-1 concentrations are not influenced in MM patients. Therefore, although it is a proliferation cytokine, it cannot be used as marker of disease activity.


Related Articles

  • Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Lamorte, S; Ferrero, S; Aschero, S; Monitillo, L; Bussolati, B; Omedè, P; Ladetto, M; Camussi, G // Leukemia (08876924);May2012, Vol. 26 Issue 5, p1081 

    Angiogenesis is considered a hallmark of multiple myeloma (MM) progression. In the present study, we evaluated the morphological and functional features of endothelial cells (ECs) derived from bone marrow (BM) of patients affected by MM (MMECs). We found that MMECs compared with normal BM ECs...

  • Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis. Shailubhai, Kunwar; Dheer, Surendra; Picker, Donald; Kaur, Gurmeet; Sausville, Edward A.; Jacob, Gary S. // Journal of Experimental Therapeutics & Oncology;2004, Vol. 4 Issue 4, p267 

    Atiprimod, a novel compound belonging to the azaspirane class of cationic amphiphilic drugs, exhibits both anti-proliferative and anti-angiogenic activities. Atiprimod inhibited proliferation of all human cancer cell lines included in the National Cancer Institute panel with IC50 values in the...

  • Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma. Sfiridaki, Aikaterini; Miyakis, Spiros; Pappa, Constantina; Tsirakis, George; Alegakis, Athanasios; Kotsis, Vasileios; Stathopoulos, Efstathios; Alexandrakis, Michael // Journal of Hematology & Oncology;2011, Vol. 4 Issue 1, p22 

    The matrix protein osteopontin has been shown to be a marker of osteoclastic activity in multiple myeloma patients, as well as a regulator of angiogenesis. We measured serum levels of osteopontin in 50 untreated multiple myeloma patients (in 25, also after treatment) and examined the relation to...

  • Bone marrow angiogenesis in multiple myeloma. Vacca, A.; Ribatti, D. // Leukemia (08876924);Feb2006, Vol. 20 Issue 2, p193 

    Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. It is induced by plasma cells via angiogenic factors with the transition from monoclonal gammopathy of undetermined significance (MGUS) to MM, and probably with loss of angiostatic activity on...

  • Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Pour, Ludek; Svachova, Hana; Adam, Zdenek; Almasi, Martina; Buresova, Lucie; Buchler, Tomas; Kovarova, Lucie; Nemec, Pavel; Penka, Miroslav; Vorlicek, Jiri; Hajek, Roman // Annals of Hematology;Apr2010, Vol. 89 Issue 4, p385 

    Angiogenesis plays a significant role in the pathogenesis of multiple myeloma (MM). We have measured concentrations of angiogenesis activators, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and hepatocyte growth factor (HGF), and inhibitors, including...

  • Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma. Timm, M. M.; Kimlinger, T. K.; Haug, J. L.; Kline, M. P.; Greipp, P. R.; Rajkumar, S. V.; Kumar, S. K. // Leukemia (08876924);Oct2006, Vol. 20 Issue 10, p1863 

    Multiple myeloma is characterized by the proliferation of clonal plasma cells that have a heterogeneous expression of various cell surface markers, precluding successful use of monoclonal antibodies for therapeutic targeting of the tumor cell. Thymoglobulin (rabbit-derived polyclonal...

  • Maintenance lenalidomide prolonged PFS in transplant-ineligible multiple myeloma.  // Hem/Onc Today;6/10/2012, Vol. 13 Issue 11, p22 

    The article reports on a study which found that multiple myeloma patients who are ineligible for stem cell transplants, have a longer progression-free survival rate when placed on maintenance therapy with lenalidomide.

  • Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Stessman, H A F; Mansoor, A; Zhan, F; Janz, S; Linden, M A; Baughn, L B; Van Ness, B // Leukemia (08876924);Oct2013, Vol. 27 Issue 10, p2075 

    A letter to the editor is presented in response to the article related to aspects of mouse model of myeloma and treatment of multiple myeloma patients in the May 31, 2013 issue.

  • Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Menu, E; Kooijman, R; Valckenborgh, E Van; Asosingh, K; Bakkus, M; Camp, B Van; Vanderkerken, K; Van Valckenborgh, E; Van Camp, B // British Journal of Cancer;3/8/2004, Vol. 90 Issue 5, p1076 

    Insulin-like growth factor-1 (IGF-1) has been described as an important factor in proliferation, cell survival and migration of multiple myeloma (MM) cells. Angiogenesis correlates with development and prognosis of the MM disease. Vascular endothelial growth factor (VEGF) is one of the prominent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics